- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02053350
Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection
Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection: A Randomized, Double-blind, Placebo-controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase II randomized, placebo-controlled, double-blinded, dose-ranging study to determine optimal effective dose and safety of AQ between 0, 4, 24, and 44 g doses administered orally for ten days concurrent with standard treatment (oral vancomycin at UVa) among first time incident cases of uncomplicated CDI in hospitalized persons age 50 and older. Our hypothesis is that AQ will reduce recurrence (primary outcome) and mortality (secondary outcome) at 60 days post-treatment. Furthermore, we hypothesize that alanyl-glutamine supplementation will be associated with decreased intestinal and systemic inflammation and improvement of intestinal microbial and metabolic profiles. We plan to enroll 260 patients, equally divided into 4 arms. Upon enrollment, participants will be randomized to either receive AQ at 4, 24, or 44 g or placebo (water). Study agent is administered once a day, orally or enterally, if feeding tube is present. Because we are enrolling subjects over a longer period of time, we will utilize block randomization to ensure that relative temporal balance is maintained throughout the trial. Participants will be followed up daily during treatment for adverse event monitoring and weekly for 60 days post-treatment for recurrences and survival. Blood, urine and stool specimens will be collected at days 0, 10 and 70 to assay for markers of inflammation and microbial and metabolic profiling.
The data set utilized for all initial baseline feature and demographic reporting will be the Intention to Treat Analysis Dataset, which will be comprised of all randomized participants. The primary dataset will be a Modified Intention to Treat Analysis Dataset for all endpoints, comprised of all participants who took at least one dose of study intervention (placebo or treatment), regardless of completeness of follow-up outcome data. The Safety Analysis Dataset will be all participants who took at least one dose of study intervention. The Per Protocol Analysis Dataset will be those patients who took at least 9 doses of study intervention for 9 days of the treatment period (10 days). Analysis will utilize ANOVA unless statistically significant differences in the distribution of baseline characteristics or features of non-normality are detected and relevant, at which point contingency utilization of ANCOVA, logistic regression, or other approaches as appropriate will be implemented. Treatment group level rates will be presented as incidence risk ratios relative to the control (placebo) group with 95% confidence intervals.
Safety endpoints will be evaluated on an individual AE by AE event via the DSMB and utilizing summary statistics during treatment and through duration of follow up. Adverse events will be presented by System Organ Class and will include information on start and stop date, severity, projected relationship, expectedness, and outcome and duration (the latter two after the event is considered to have concluded).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult of either gender, 18 years or older, with C. difficile infection (CDI)
- Diarrhea associated with C. difficile positive stool assay
- Within 48 hours of receiving either metronidazole for mild-moderate disease or vancomycin for severe uncomplicated disease
- Admitted in the hospital at the time of enrollment
- Ability to provide informed consent
- Have an understanding of study procedures
- Ability to comply with study procedures for the entire length of the study
Exclusion Criteria:
- Hypotension or shock
- Megacolon or moderate to severe ileus
- Acute abdomen
- Severe leukocytosis (WBC > 20,000 cells /µL)
- Admission to intensive care unit on enrollment
- Inability to tolerate oral medication
- Other known etiology of diarrhea (e.g. other enteric pathogen, other intestinal disease)
- Inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis)
- Enrollment in another investigational drug trial
- Currently receiving other alternative treatment for CDI (e.g. antibiotics other than metronidazole or vancomycin; probiotics; immunoglobulin therapy; fecal transplant)
- Pregnancy
- Unavailable for follow-up visits
- Life expectancy of < 6 months
- Chronic liver disease or in subjects without known liver disease, ALT > 3x normal
- Chronic kidney disease or in subjects without known kidney disease, estimated Creatinine clearance of < 30 ml/min, even after rehydration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Alanyl-glutamine
Alanyl-glutamine, 44g, taken by mouth daily for 10 days.
|
Alanyl-glutamine, 44g, taken by mouth daily for 10 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Recurrent C. Difficile Infection
Time Frame: At day forty
|
Day 40 clinical failure - clinical failure includes death or CDI recurrence assessed 40 days post randomization or lack of clinical cure
|
At day forty
|
Mortality
Time Frame: Up to 6 months after end of treatment
|
Death from any cause at days 40, 70 and 190
|
Up to 6 months after end of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cirle A. Warren, M.D., University of Virginia
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17576
- 17576 Protocol_Alanyl_Glutami (Other Identifier: UVA PI)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clostridium Difficile Infection
-
Vedanta Biosciences, Inc.CompletedClostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection RecurrenceUnited States, Canada
-
Vedanta Biosciences, Inc.Not yet recruitingClostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection
-
University of PennsylvaniaTerminatedSevere Clostridium Difficile Infection | Severe-Complicated/Fulminant Clostridium Difficile InfectionUnited States
-
Mikrobiomik Healthcare Company S.L.CompletedRecurrent Clostridium Difficile Infection | Primary Clostridium Difficile InfectionSpain
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences Institute; North Carolina...CompletedClostridium DifficileUnited States
-
University Health Network, TorontoTerminatedRecurrent Clostridium Difficile Infection | Laboratory Confirmed Clostridium Difficile InfectionCanada
-
University of Wisconsin, MadisonAgency for Healthcare Research and Quality (AHRQ)Enrolling by invitationClostridium Difficile Infection | Clostridium Difficile | C Difficile ColitisUnited States
-
Hospital Universitario Evangelico de CuritibaNot yet recruitingClostridium Difficile Infections
-
DeinoveRecruitingClostridium Difficile (C. Difficile)United States, Canada
-
MJM BontenUniversiteit Antwerpen; Universitätsklinikum Köln; Da VolterraCompletedClostridium DifficileGermany, Spain, France, Greece, Netherlands, Romania
Clinical Trials on Alanyl-glutamine
-
University of VirginiaImperial College LondonRecruitingClostridium Difficile Infection | Clostridium Difficile Diarrhea | Clostridioides Difficile Infection | Clostridia Difficile ColitisUnited States
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Scandinavian Critical Care Trials GroupTerminated
-
Instituto Mexicano del Seguro SocialCompletedInsufficiency;CardiacMexico
-
Air Force Specialized Hospital, Cairo, EgyptRecruiting
-
University Hospital MuensterFresenius Kabi; IZKF (Interdisciplinary Centre for Clinical Research (IZKF)...CompletedAcute Kidney Injury | Cardiac SurgeryGermany
-
Children's Hospital Medical Center, CincinnatiUniversidade Federal do CearáCompletedDiarrhea | Malnutrition | Environmental EnteropathyBrazil
-
Centre Hospitalier Universitaire de BesanconUnknownBiomarkers | Enteral Nutrition | Intensive Care Unit
-
Temple Therapeutics BVCompletedPelvic AdhesionsUkraine
-
Medical Center AlkmaarUnknownColon CarcinomaNetherlands